The NMDA Receptor Competitive Antagonist CPP Modulates Benzodiazepine Tolerance and Discontinuation
The DOI matches its Crossref record.
Abstract
Benzodiazepine discontinuation is characterized by a syndrome of increased activity and reduced seizure threshold that is similar to effects mediated by the glutamatergic system. To elucidate the involvement of the glutamatergic system in benzodiazepine tolerance and discontinuation, we administered lorazepam, the NMDA antagonist CPP, and the combination of these compounds either concomitantly or consecutively to mice via osmotic pumps and evaluated pentylenetetrazole-induced seizure threshold, open-field activity, and benzodiazepine receptor binding during and after chronic administration. Animals receiving lorazepam alone developed partial tolerance at 7 days and complete tolerance at 14 days to the anticonvulsant effects of lorazepam. This effect was partly attenuated by CPP coadministration with lorazepam. This combination produced only partial tolerance. A reduction in seizure threshold was observed 4 days after discontinuation of lorazepam alone. This effect was abolished by coadministration of CPP with lorazepam and by CPP administration during the withdrawal period. Benzodiazepine binding in most structures examined was significantly reduced at 14 days during chronic lorazepam administration (versus 1 day), and coadministration of CPP did not alter this decrement. After lorazepam discontinuation, binding was increased at 4 and 7 days versus chronically treated animals and versus vehicle within the cerebral cortex. This effect was abolished by coadministration of CPP as well as by CPP administration during the lorazepam withdrawal period. These data support the involvement of the glutamatergic system in benzodiazepine tolerance and discontinuation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Also, lorazepam-induced tolerance to its acute anticonvulsant effects was partially prevented with simultaneous CPP treatment [122].”
From Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective Receptor Modulators? (2012) · cites this paper as [122]
Citations
Cites
Still being checked.
Cited by
Vinkers, C. H., & Olivier, B. (2012) · Advances in Pharmacological Sciences · doi:10.1155/2012/416864 · Cited by 195
“Also, lorazepam-induced tolerance to its acute anticonvulsant effects was partially prevented with simultaneous CPP treatment [122].”
BackgroundNeuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence
Allison, C., & Pratt, J. A. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(03)00029-9 · Cited by 160
Low-dose subcutaneous ketamine infusion and morphine tolerance
Bell, R. F. (1999) · Pain · doi:10.1016/s0304-3959(99)00096-2 · Cited by 98
Izzo, E., Auta, J., Impagnatiello, F., Pesold, C., Guidotti, A., & Costa, E. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051628698 · Cited by 90
GABAA receptor subtypes and benzodiazepine use, misuse, and abuse
Engin, E. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1060949 · Cited by 94
Cheng, T., Wallace, D. M., Ponteri, B. B., & Tuli, M. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s164307 · Cited by 66
“It appears that NMDA upregulation happens acutely after benzodiazepine administration, because NMDA antagonists dizocilpine (MK-801) and CPP were able to prevent tolerance to sedative and withdrawal effects after benzodiazepine administration.(102,103) While the NMDA antagonist can suppress withdrawal symptoms in acut…”
Bisaga, A. M., Popik, P., Bespalov, A., & Danysz, W. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.10.2233 · Cited by 56
Seizures in the Adult Intensive Care Unit
Varelas, P. N., & Mirski, M. A. (2001) · Journal of Neurosurgical Anesthesiology · doi:10.1097/00008506-200104000-00016 · Cited by 53
Tzschentke, T., & Schmidt, W. (1998) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(98)01255-3 · Cited by 48
Xiang, K., & Tietz, E. I. (2007) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3282d28f2b · Cited by 42
de la Peña, J. B., Lee, H. C., Peña, I. D., Woo, T. S., Yoon, S. Y., Lee, H. L., Han, J. S., Lee, J. I., Cho, Y. J., Shin, C. Y., et al. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.05.038 · Cited by 36
Allison, C., & Pratt, J. A. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300800 · Cited by 27
“Several studies have also provided evidence for a role for NMDA receptor antagonists in blocking the behavioral components of BZ tolerance and withdrawal (Steppuhn and Turski, 1993; File and Fernandes, 1994; Koff et al, 1997; Tsuda et al, 1998a, b).”
BackgroundShen, G., Sickle, B. J. V., & Tietz, E. I. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.61 · Cited by 26
Bazyan, A. S., & van Luijtelaar, G. (2013) · ISRN Neurology · doi:10.1155/2013/875834 · Cited by 23
Costa, E., Auta, J., & Guidotti, A. (2001) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-56833-6_8 · Cited by 16
Kang, Y., Saito, M., & Toyoda, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020563 · Cited by 15
Talarek, S., Listos, J., Orzelska‐Górka, J., Serefko, A., & Kotlinska, J. H. (2017) · Neurotoxicity Research · doi:10.1007/s12640-017-9810-1 · Cited by 16
de la Peña, J. B., & Cheong, J. H. (2016) · Drug Testing and Analysis · doi:10.1002/dta.1987 · Cited by 18
Lorazepam Attenuates the Behavioral Effects of Dizocilpine
Fahey, J. M., Pritchard, G. A., Pratt, J. S., Shader, R. I., & Greenblatt, D. J. (1999) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(98)00145-2 · Cited by 12
Self-citationBitran, D., & Solano, S. M. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2194-6 · Cited by 8
The effect of chronic lorazepam administration in aging mice
Fahey, J. M., Pritchard, G. A., Reddi, J. M., Pratt, J. S., Grassi, J. M., Shader, R. I., & Greenblatt, D. J. (2006) · Brain Research · doi:10.1016/j.brainres.2006.08.017 · Cited by 7
Self-citationThe Pharmacodynamics of PK 11195 in Diazepam-Dependent Male and Female Rats
Sloan, J. W., Wala, E. P., Jing, X., & Holtman, J. R. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(00)00239-2 · Cited by 8
Warlick, H., Leon, L., Patel, R., Filoramo, S., Knipe, R., Joubran, E., Levy, A., Nguyen, H., & Rey, J. A. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-08110-9 · Cited by 6
NMDA Antagonists and Tolerance to Drugs Affecting the Central Nervous System
Khanna, J. M., Morato, G. S., & Ferreira, V. M. M. (1999) · CNS Drug Reviews · doi:10.1111/j.1527-3458.1999.tb00096.x · Cited by 4
Mother's little helper turned a foe: Alprazolam use, misuse, and abuse
Cardona-Acosta, A. M., Meisser, N., Vardeleon, N. I., Steiner, H., & Bolaños‐Guzmán, C. A. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111137 · Cited by 5
Brain glycine levels in triazolam-treated albino rats
Aburawi, S. M., Ahmed, S. S., Elhwuegi, A. S., Saad, S. F., & Attia, A. S. (2001) · Journal of Neural Transmission · doi:10.1007/s007020170054 · Cited by 4
Moghadam, N. N., Torkaman‐Boutorabi, A., Farhoudian, A., & Razaghi, E. M. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177643 · Cited by 1
Biological behavior of 1,4-benzodiazepines and 1,4-benzothiazepines
Zamani, F., Zamani, N., Suzuki, T., & Doustkhah, E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824516-3.00010-0 · Cited by 2
Song, J. H. (2007) · OhioLink ETD Center (Ohio Library and Information Network)
Xiang, K. (2007) · OhioLink ETD Center (Ohio Library and Information Network)
Illicit Drugs and Toxins and Critical Care Seizures
McNulty, M. L., Luft, A. R., & Bleck, T. P. (2017) · Springer eBooks · doi:10.1007/978-3-319-49557-6_21
Critical Care Seizures Related to Illicit Drugs and Toxins
Luft, A. R. (2008) · Humana Press eBooks · doi:10.1007/978-1-59259-841-0_13
Critical Care Seizures Related to Illicit Drugs and Toxins
Luft, A. R. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-532-3_14
Metadata
- Authors
- Koff, J. M., Pritchard, G. A., Greenblatt, D. J., & Miller, L. G.
- Affiliations
- Tufts University (US)
- ORCID
- Greenblatt, David J.
- Venue
- Pharmacology
- Publisher
- S. Karger AG
- Published
- 2008-06-10
- Volume
- 55
- Issue
- 5
- Pages
- 217-227
- ISSN
- 0031-7012 (ISSN-L)
- 1423-0313
- OpenAlex
- W2017337653
- Cited by
- 33
- References
- 0
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 1 · 2022: 2 · 2020: 1 · 2018: 1 · 2017: 2 · 2016: 1 · 2013: 1 · 2012: 2
- FWCI
- 0.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- karger.com/pages/terms-and-conditions (vor)
- karger.com/pages/terms-and-conditions (tdm)
- Locations
- Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01mh047598-03)
- National Institute of Mental Health (MH 34223, MH-47598)
- National Institute on Drug Abuse (DA05258)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- benzodiazepine tolerance, benzodiazepine discontinuation, NMDA receptor antagonists, CPP, lorazepam, glutamatergic system, seizure threshold, benzodiazepine binding, benzodiazepine withdrawal, pentylenetetrazole-induced seizures, cerebral cortex
- MeSH terms
- Animals, Cerebral Cortex, Drug Interactions, Drug Tolerance, Hippocampus, Lorazepam, Male, Motor Activity, Pentylenetetrazole, Piperazines, Receptors, GABA-A, Seizures, Substance Withdrawal Syndrome, Receptors, N-Methyl-D-Aspartate, Excitatory Amino Acid Antagonists, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.